ADC Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Biopôle 3b, Epalinges, Vaud, 1066, Switz...Phone Number
+41 216530200Website
www.adctherapeutics.comRevenue
$79.2 MillionStock Symbol
ADCTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About ADC Therapeutics
ADC Therapeutics SA is a publicly traded, commercial-stage oncology biotechnology company headquartered in Epalinges, Switzerland, and listed on the NYSE under the ticker ADCT. Founded in 2011, the company is a global pioneer in the development of next-generation antibody drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. Its flagship product, ZYNLONTA (loncastuximab tesirine), is an FDA-approved CD19-directed ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ADC Therapeutics maintains an active clinical pipeline focused on expanding ZYNLONTA into earlier lines of therapy and additional lymphoma indications, alongside preclinical programs targeting a range of tumor antigens. The company operates globally with R&D in London, clinical and commercial operations in New Jersey, and chemistry, manufacturing, and controls (CMC) in the San Francisco Bay Area.Explore more
ADC Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ADC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if ADC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once ADC Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ADC Therapeutics recently announced quarterly report
ADC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ADC Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ADC Therapeutics
Check out if ADC Therapeutics is spiking on competitors!
Product Launch: Get notified when ADC Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined ADC Therapeutics as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
ADC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ADC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ADC Therapeutics.
ADC Therapeutics financials insights
Gather financial insights about ADC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$40M
2015
Unspecified
$80M
2016
Share Placement
$105M
Series D
$105M
2019
Series E
$303M
2020
Stock Offering
$267.6M
2022
Private Equity
$6.3M
Debt
$175M
2025
Stock/Share Issuance
$100M
ADC Therapeutics Tech Stack
A closer look at the technologies used by ADC Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Earnings
Earnings, Finance
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
ADC Therapeutics News & Media
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with...ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call May 4, 2026 8:30 AM EDTCompany ParticipantsNicole Riley - Head of Investor Relations & Corporate...ADC Therapeutics Q1 Earnings Call Highlights
ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial. ZYNLONTA revenue rises to $20 million as cADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding ADC Therapeutics
Sign Up For FreeTo access detailed company insights
ADC Therapeutics SA is a publicly traded, commercial-stage oncology biotechnology company headquartered in Epalinges, Switzerland, and listed on the NYSE under the ticker ADCT. Founded in 2011, the company is a global pioneer in the development of next-generation antibody drug conjugates (ADCs) for the treatment of hematologic malignancies and soli... Read More
